Please assess the completion status of the following clinical trial:

Trial Title: SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age:18-70 years~2. Histologically or cytologically confirmed locally advanced and/or metastatic NSCLC or recurrent NSCLC (≤9 months from date of diagnosis to randomized ), epidermal growth factor receptor-wild type, Anaplastic Lymphoma Kinase-wild type or unknown mutation~3. At least one lesion that can be accurately measured and has not been received local treatments such as radiotherapy and cryotherapy~4. Relapse or failure of one first line prior platinum-based chemotherapy~5. Eastern Cooperative Oncology Group performance status 0 or 1~6. Life expectancy of at least 12 weeks~7. Adequate organ and bone marrow function as defined below(no blood transfusion or drugs for leucopenia and Platelet within 14 days before screening): (1) HB≥90g/l (2) ANC≥1.5×10\^9/l (3) PLT≥100×10\^9/l (4) BIL\<1.25×upper limit of normal (5) Alanine Aminotransferase and/or AST\<2.5×upper limit of normal (\< 5×upper limit of normal for patients with liver metastasis) (6) Cr≤1.25×upper limit of normal or Creatinine clearance rate\>45ml/min ( Cockcroft-Gault Formula) (7) Cholesterol≤1.5×upper limit of normal, Triglyceride≤2.5×upper limit of normal (8) Left ventricular ejection fraction (LVEF) greater than lower limit of normal~8. Female: child bearing potential, a negative urine or serum pregnancy test result within 7 days before randomisation, agree to use effective contraception while on treatment and for at least 6 months after end of treatment;male: agree to use effective contraception while on treatment and for at least 6 months after end of treatment~9. Patient has given written informed consent~Exclusion Criteria:~1. More than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC (except neoadjuvant or adjuvant chemotherapy )~2. Previous therapy with other VEGFR inhibitors、recombinant human endostatin、 docetaxel or immunotherapy for treatment of NSCLC~3. History of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80), Hypersensitivity to the excipients of the trial drugs or contrast medium~4. Have clinically significant cavity effusion,such as pleural effusion、 pericardial effusion or ascites and require clinical intervention~5. Active brain metastases~6. Other malignancy within the past (including primary brain tumor or Leptomeningeal tumor), other than basal cell skin cancer or carcinoma in situ of the cervix~7. Significant weight loss (\>10%) within the past 6 weeks~8. Persistence of clinically relevant therapy related toxicities from previous therapy (greater than Common Terminology Criteria for Adverse Event(CTCAE) 4.0 grade 1)~9. Treatment with surgery, chemotherapy, hormone therapy, radiotherapy, immunomodulation or monoclonal antibody therapy within the past 4 weeks and traditional chinese medicine for antitumor therapy within the past 2 weeks before start of therapy~10. Radiographical evidence of cavitary or necrotic tumours~11. Centrally located tumours with radiographical evidence (CT or MRI) of local invasion of major blood vessels~12. Greater than CTCAE 4.0 grade 2 pulmonary hemorrhage within the past one month before screening~13. History of clinically significant haemoptysis within the past 3 months (more than half a teaspoon within 24 hours )~14. History of major thrombotic or clinically relevant major bleeding event in the past 6 months~15. Prothrombin time (PT) and/or partial thromboplastin time (PTT) \> 50% of devi~    * ation of upper limit of normal~16. Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogus, if INR≤1.5, with the purpose of prevention,the use of low-dose warfarin (1mg, qd) or aspirin ( ≤ 100 mg per day ) is allowed~17. Incomplete wound healing or fracture for long time~18. Uncontrolled hypertensin with one antihypertensive agent, unstable angina, history of myocardial infarction in the past 6 months, congestive heart failure\>NYHA II, serious cardiac arrhythmia~19. Urinary protein≥++ and confirmed 24-hour urinary protein greater than 1.0g;~20. Preexisting thyroid dysfunction, even with medical therapy, thyroid function can not be maintained in the normal range~21. Uncontrolled diabetes mellitus with antidiabetic therapy~22. Current peripheral neuropathy greater than CTCAE 4.0 grade 2~23. Active or chronic hepatitis C and/or B infection with liver dysfunction~24. History of immunodeficiency diseases, other acquired or congenital immunodeficiency diseases, or history of organ transplantation~25. Serious infections requiring systemic antibiotic therapy~26. Variety of factors that affect the oral medication (such as unable to swallow, chronic diarrhea, bowel obstruction and other gastrointestinal disorders or abnormalities~27. Pregnancy or breast feeding~28. Active alcohol or drug abuse~29. Treatment in another clinical trial within the past 4 weeks before start of therapy~30. Psychological, familial, sociological, or geographical factors potentially hampering compliance with the study protocol and follow-up schedule~31. According to the investigator, other conditions that may increase the risk associated with patient safety and study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SHR1020 plus Docetaxel (Type: EXPERIMENTAL): None
- Placebo plus Docetaxel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues